Skip to main content

Histrelin Pregnancy and Breastfeeding Warnings

Brand names: Supprelin LA, Vantas

Medically reviewed by Drugs.com. Last updated on Aug 16, 2023.

Histrelin Pregnancy Warnings

Use is contraindicated.

US FDA pregnancy category: X

Comments:
-This drug can harm a developing fetus.
-Adequate methods of contraception should be encouraged.
-Verify negative pregnancy status in females of reproductive potential prior to initiating therapy.
-If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.

Animal studies have revealed evidence of embryotoxicity and teratogenicity (e.g., spontaneous abortions, major fetal abnormalities, increased fetal mortality, decreased fetal weights, reduced fertility). There are no controlled data in human pregnancy.

AU TGA pregnancy category X: Drugs which have such a high risk of causing permanent damage to the fetus that they should not be used in pregnancy or when there is a possibility of pregnancy.

See references

Histrelin Breastfeeding Warnings

This drug is not indicated for use in female patients.

Excreted into human milk: Unknown
Excreted into animal milk: Yes

Comments:
-This drug can harm a nursing infant.

See references

References for pregnancy information

  1. (2010) "Product Information. Vantas (histrelin)." Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)
  2. (2010) "Product Information. Supprelin LA (histrelin)." Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)

References for breastfeeding information

  1. (2010) "Product Information. Vantas (histrelin)." Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)
  2. (2010) "Product Information. Supprelin LA (histrelin)." Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.